Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on January 17, 2020, covering events occurring on January 14 and January 16, 2020. The Company is a Delaware corporation trading on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational milestones rather than financial performance data.
Material Changes and Operational Events
- Patent Award: On January 14, 2020, the Company was awarded a fifth utility patent covering its PURE EP System.
- Clinical Trial Expansion: On January 16, 2020, the Company installed its PURE EP System at Mayo Clinic in Florida to conduct patient cases under the "Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)."
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future earnings, or a discussion of risks and contingencies. The report serves solely to disclose the patent award and the commencement of clinical trial activities at a new site.
Investor Verification Checklist
- Verify the details of the fifth utility patent awarded to BioSig Technologies.
- Confirm the status and enrollment progress of the PURE EP 2.0 Study at Mayo Clinic in Florida.
- Review the full text of the press releases filed as Exhibits 99.1 and 99.2 for additional technical or commercial context.